Sinogen will soon initiate clinical trials of its first product SalMet-Vec® in the US.

Sinogen's first-in-class broad-spectrum antitumor product SalMet-Vec^®  has obtained two IND approvals from the FDA for intravenous and intratumoral administration, and the registered phase I/IIa clinical trials for intravenous and intratumoral injection will soon be conducted in the United States. SalMet-Vec^® is the world's first tumor-targeted amino acid metabolism regulation therapy biological product and will be the first-in-class novel biological antitumor drug with rapid and broad-spectrum antitumor activity.

SalMet-Vec^®

Background: SalMet-Vec^® carries and expresses methioninase through attenuated Salmonella vector to exert precisely targeted antitumor effects on the basis of tumor metabolism inhibition. SalMet-Vec^® is capable of active targeting, can be administered through multiple routes including intratumoral, intravenous, and arterial infusion without special modification of the delivery system, and has shown outstanding efficacy and safety in animal experiments and investigator-sponsored clinical studies in multiple malignant tumors including liver cancer, sarcoma, and melanoma. SalMet-Vec^® is fully developed by Sinogen which owns the global intellectual property rights of SalMet-Vec^®.